A Nut for Every Bolt: Subunit-Selective Inhibitors of the Immunoproteasome and Their Therapeutic Potential

Area of Science:

• Molecular Biology
• Immunology
• Pharmacology

Background:

• The 20S proteasome core particle (CP) is central to protein degradation and cellular processes.
• CP inhibitors are used in treating blood cancers, but can cause cytotoxicity.
• The immunoproteasome (iCP), a CP variant, offers a therapeutic target for autoimmune diseases with potentially fewer side effects.

Purpose of the Study:

• To review prominent immunoproteasome (iCP) inhibitors.
• To discuss their scientific and medicinal applications.
• To highlight recent trends in pan-immunoproteasome inhibitors, including KZR-616.

Main Methods:

• Literature review of preclinical and clinical studies on iCP inhibitors.
• Analysis of chemical structures, potency, and subunit selectivity of identified inhibitors.
• Examination of therapeutic potential in autoimmune and inflammatory diseases.

Main Results:

• Several natural and synthetic iCP inhibitors have been identified with varying characteristics.
• Selective iCP inhibition demonstrates efficacy in preclinical models of autoimmune diseases.
• Pan-immunoproteasome inhibitors, such as KZR-616, have progressed to Phase II clinical trials.

Conclusions:

• Selective immunoproteasome inhibition is a promising strategy for autoimmune disease treatment.
• KZR-616 represents a leading candidate for chronic inflammatory conditions.
• Further research into iCP inhibitors could yield novel therapeutic agents.